DeDPP4 是一种 DPP-4 PROTAC 降解剂,可诱导胰高血糖素样肽-1 (GLP-1) 持续升高,增强葡萄糖耐量,使血糖持续降低,并在 2 型糖尿病动物模型中实现长期血糖调控,同时可在癌细胞中介导剂量依赖性的 DPP-4 耗竭,还可在 2 型糖尿病动物模型的肝脏和脂肪组织中靶向降解 DPP-4,因此可用于 2 型糖尿病、非小细胞肺癌的研究(粉色:DPP-4 配体 (MS-P11978);蓝色:Cereblon 配体 (MS-P24078);黑色:连接子 (MS-N60807))。
DeDPP4
产品编号: MS-W56433 分子式: C36H38N8O8 分子量: 710.74
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

DeDPP4 是一种 DPP-4 PROTAC 降解剂,可诱导胰高血糖素样肽-1 (GLP-1) 持续升高,增强葡萄糖耐量,使血糖持续降低,并在 2 型糖尿病动物模型中实现长期血糖调控,同时可在癌细胞中介导剂量依赖性的 DPP-4 耗竭,还可在 2 型糖尿病动物模型的肝脏和脂肪组织中靶向降解 DPP-4,因此可用于 2 型糖尿病、非小细胞肺癌的研究(粉色:DPP-4 配体 (MS-P11978);蓝色:Cereblon 配体 (MS-P24078);黑色:连接子 (MS-N60807))。

生物实验数据

生物活性 DeDPP4 is a DPP-4 PROTAC degrader that induces sustained elevation of glucagon-like peptide-1 (GLP-1), enhances glucose tolerance, achieves sustained blood glucose reduction, and enables long-term glycemic control in type 2 diabetes animal models; it also mediates dose-dependent DPP-4 depletion in cancer cells and targets DPP-4 degradation in the liver and adipose tissue of type 2 diabetes animal models, and thus can be used for research on type 2 diabetes and non-small cell lung cancer (pink: DPP-4 ligand (MS-P11978); blue: Cereblon ligand (MS-P24078); black: linker (MS-N60807)).
IC50 & Target

Cereblon

 

DPP-4

 

体外研究
(In Vitro)

DeDPP4 (10 μg/mL; 4 h) 可通过内吞途径被内化进入 A549 细胞,在 10 μg/mL 浓度下孵育 4 h 后可检测到细胞内荧光。
DeDPP4 (0-1250 nM, 24-48 h) 可在 A549 细胞中诱导 DPP-4 呈剂量和时间依赖性降解。

Western Blot Analysis

Cell Line: A549 human nonsmall cell lung cancer cells
Concentration: 0, 5, 25, 125, 625, 1250 nM (24 h incubation); 0, 1, 2, 3, 5, 10 μM (24 h incubation); 500 nM (4-48 h incubation); 2 μM (1-48 h incubation)
Incubation Time: 24 h (5-1250 nM, 1-10 μM); 4-48 h (500 nM); 1-48 h (2 μM)
Result: Induced dose-dependent DPP-4 degradation in A549 cells, with pronounced efficacy at concentrations above 625 nM;
Showed a slight hook effect at 1-10 μM.
Induced time-dependent degradation, with increasing efficiency over 48 h at both 500 nM and 2 μM, consistent with PROTAC-mediated degradation kinetics.

Immunofluorescence

Cell Line: A549 human nonsmall cell lung cancer cells
Concentration: 500 nM
Incubation Time: 24 h
Result: Caused a marked decrease in red DPP-4 fluorescence intensity in treated cells compared to the control group.
体内研究
(In Vivo)

DeDPP4 (5-10 mg/kg;静脉注射;单次给药,每 2 天 1 次;持续 4 周) 在 2 型糖尿病 db/db 小鼠中发挥剂量依赖性的持久降糖作用,其中 10 mg/kg 静脉注射可使血糖维持降低状态超过 60 h,同时可改善胰岛素敏感性、保护胰腺 β 细胞功能、调节脂质代谢,并通过降解 DPP-4 蛋白发挥器官损伤保护作用。

Animal Model: leptin receptor-deficient (db/db) (10-week-old, male)
Dosage: 5 mg/kg (4-week study); 10 mg/kg (single-dose efficacy study; 4-week study)
Administration: i.v.; every 2 days; 4 weeks (5 mg/kg, 10 mg/kg 4-week study); i.v.; single dose (10 mg/kg efficacy longevity study)
Result: Maintained reduced blood glucose levels for over 60 h, with sustained hypoglycemia observed for up to 48 h (10 mg/kg single dose).
Reduced fasting blood glucose levels more effectively than 5 mg/kg DeDPP4, and lowered hemoglobin A1c (HbA1c) levels to ~7% after 4 weeks of treatment (10 mg/kg).
Reduced blood glucose to 10.6 mmol/L within 60 min during OGTT, with a significantly lower area under the blood glucose curve (AUC) than the model group (10 mg/kg).
Reduced the homeostasis model assessment of insulin resistance (HOMA-IR) more effectively than alogliptin, and preserved pancreatic β-cell function (HOMA-β) (10 mg/kg).
Significantly increased serum glucagon-like peptide-1 (GLP-1) levels compared to alogliptin (10 mg/kg).
Reduced serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and free fatty acids (FFA) more effectively than 5 mg/kg DeDPP4 or alogliptin, while increasing high-density lipoprotein cholesterol (HDL-C) (10 mg/kg).
Significantly reduced serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CREA) levels (10 mg/kg).
Preserved pancreatic islet morphology with increased β-cell mass and reduced α/β cell ratio (10 mg/kg).
Induced a greater reduction in hepatic DPP-4 protein levels than 5 mg/kg DeDPP4 (10 mg/kg).

化学信息

分子量 710.74
分子式 C36H38N8O8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础